Results 161 to 170 of about 38,272 (314)

Supplementary Material for: The association between dapagliflozin use and the risk of post contrast acute kidney injury in patients with type 2 diabetes and chronic kidney disease: a propensity-matched analysis

, 2023
Liu T, Jian Xiao, Li L, Chu S., Zhongjie Fan   +4 more
openalex   +1 more source

Dapagliflozin ameliorates diabetes-induced spermatogenic dysfunction by modulating the adenosine metabolism along the gut microbiota-testis axis

Scientific Reports
Male infertility is one of the most common complications of diabetes mellitus (DM). Dapagliflozin is widely used to manage the type II DM. This study aimed to assess the dapagliflozin’s effects on the spermatogenesis by administering either dapagliflozin
Zirun Jin, Yalei Cao, Qi Wen, Haitao Zhang, Zhuofan Fang, Qiancheng Zhao, Yu Xi, Zhi-Chao Luo, Hui Jiang, Zhe Zhang, Jing Hang   +10 more
semanticscholar   +1 more source

Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort

Diabetic Medicine, Volume 43, Issue 2, February 2026.
Abstract Aims This study assesses national trends and, socio‐demographic and clinical factors associated with polypharmacy and potentially in appropriate prescribing among people with type 2 diabetes in Scotland from 2012 to 2022. Methods Retrospective cohort study using nationwide data from the Scottish Care Information – Diabetes database ...
William Berthon, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Amanda de Assuncao Santiago Fernandes, Lauren E. Walker, Rory J. McCrimmon, Helen M. Colhoun, David A. McAllister, Peter Hanlon   +8 more
wiley   +1 more source

Decision letter for "Dapagliflozin Reduces Systolic Blood Pressure and Modulates Vasoactive Factors"

, 2020

openalex   +1 more source

The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis

Nephrology, Dialysis and Transplantation
Background Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure.
Phil McEwan, Peter D. Gabb, Jason A. Davis, Juan Jose, Garcia Sanchez, C. D. Sjöström, Salvatore Barone, Pavlos Kashioulis, Mario Ouwens, Syd Cassimaty, Ricardo Correa-Rotter, P. Rossing, David C. Wheeler, Hiddo J. L. Heerspink   +13 more
semanticscholar   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source

Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels

International Journal of Molecular Sciences
The sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin is increasingly used in the treatment of diabetes and heart failure. Dapagliflozin has been associated with reduced incidence of atrial fibrillation (AF) in clinical trials.
M. E. Müller, Finn Petersenn, Juline Hackbarth, Julia Pfeiffer, Heike Gampp, Norbert Frey, P. Lugenbiel, Dierk Thomas, Ann-Kathrin Rahm   +8 more
semanticscholar   +1 more source

Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 946-959, February 2026.
Abstract Background Metformin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) may reduce the risk of adiposity‐related cancers in patients with type 2 diabetes (T2D). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body ...
Alex E. Henney, Megan Heague, David R. Riley, Theresa J. Hydes, Matthew Anson, Uazman Alam, Daniel J. Cuthbertson   +6 more
wiley   +1 more source

One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 972-981, February 2026.
Abstract Aims Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage.
Louise A. Donnelly, Katyayeni Singh, Rory J. McCrimmon, Ewan R. Pearson   +3 more
wiley   +1 more source

Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study

Frontiers in Pharmacology
ObjectivesThis study compared the ischemic cardiovascular events (iCVEs) effectiveness and safety of initiating empagliflozin or dapagliflozin with those of dipeptidyl peptidase-4 inhibitors (DPP-4is), as well as the comparative effects between ...
Hayeon Kim, Jun-Ho Seo, Jin Hyun Nam, Yejee Lim, Kyung Hee Choi, Kyungim Kim, Kyungim Kim   +6 more
doaj   +1 more source